Funding news
Rejuvenate Bio logo

Rejuvenate Bio Raises $6.

Recently funded · $6.0M Series aHospitals and Health CareView source

Get the full Rejuvenate Bio company profile

Access contacts, investors, buying signals & more

Open in Dashboard

A biotech firm aiming to fundamentally reverse chronic age-related diseases, Rejuvenate Bio, has secured $6.0M in Series A funding. The company is developing therapies that target the core drivers of conditions like heart disease, metabolic disease, and kidney failure in humans.

Rejuvenate Bio's mission centers on unlocking the power of gene expression and epigenetic reprogramming. By leveraging these biological mechanisms, the firm seeks to tackle pre-existing ailments and potentially alter the course of aging-related health decline.

Other recently funded companies

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
GRAIL logo

GRAIL

United States

$7.1B
4
Illumina logo

Illumina

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series a rounds

Companies that recently closed a Series a round.

#CompanyAmount
1
Maneva logo

Maneva

Canada

$27.0M
2
Infinity Constellation logo

Infinity Constellation

$24.0M
3
Fesarius Therapeutics logo

Fesarius Therapeutics

United States

$20.0M
4
Pi logo

Pi

Turkey

$35.0M
5
Social Hardware logo

Social Hardware

India

$1.1M